![]() |
Name |
Hexacontane
|
Molecular Formula | C60H122 | |
IUPAC Name* |
hexacontane
|
|
SMILES |
CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCC
|
|
InChI |
InChI=1S/C60H122/c1-3-5-7-9-11-13-15-17-19-21-23-25-27-29-31-33-35-37-39-41-43-45-47-49-51-53-55-57-59-60-58-56-54-52-50-48-46-44-42-40-38-36-34-32-30-28-26-24-22-20-18-16-14-12-10-8-6-4-2/h3-60H2,1-2H3
|
|
InChIKey |
OCWUCHKZAHTZAB-UHFFFAOYSA-N
|
|
Synonyms |
Hexacontane; 7667-80-3; N-HEXACONTANE; EINECS 231-643-7; Hexacontane, 98%; DTXSID00227472; ZINC150348531; FT-0765285; Q20890380; 6A8D8087-E5DB-4A13-B9AD-8D29E4237380
|
|
CAS | 7667-80-3 | |
PubChem CID | 24318 | |
ChEMBL ID | NA |
Chemical Classification: |
|
|
---|
Molecular Weight: | 843.6 | ALogp: | 32.1 |
HBD: | 0 | HBA: | 0 |
Rotatable Bonds: | 57 | Lipinski's rule of five: | Rejected |
Polar Surface Area: | 0.0 | Aromatic Rings: | 0 |
Heavy Atoms: | 60 | QED Weighted: | 0.042 |
Caco-2 Permeability: | -6.26 | MDCK Permeability: | 0.00000002 |
Pgp-inhibitor: | 0 | Pgp-substrate: | 0 |
Human Intestinal Absorption (HIA): | 0.04 | 20% Bioavailability (F20%): | 0.001 |
30% Bioavailability (F30%): | 1 |
Blood-Brain-Barrier Penetration (BBB): | 0 | Plasma Protein Binding (PPB): | 122.57% |
Volume Distribution (VD): | 9.717 | Fu: | 0.08% |
CYP1A2-inhibitor: | 0.001 | CYP1A2-substrate: | 0.041 |
CYP2C19-inhibitor: | 0.016 | CYP2C19-substrate: | 0.032 |
CYP2C9-inhibitor: | 0 | CYP2C9-substrate: | 0.997 |
CYP2D6-inhibitor: | 0 | CYP2D6-substrate: | 0 |
CYP3A4-inhibitor: | 0.013 | CYP3A4-substrate: | 0 |
Clearance (CL): | 3.241 | Half-life (T1/2): | 0 |
hERG Blockers: | 0.519 | Human Hepatotoxicity (H-HT): | 0 |
Drug-inuced Liver Injury (DILI): | 0.7 | AMES Toxicity: | 0.014 |
Rat Oral Acute Toxicity: | 0.001 | Maximum Recommended Daily Dose: | 0.141 |
Skin Sensitization: | 0.998 | Carcinogencity: | 0.001 |
Eye Corrosion: | 0.999 | Eye Irritation: | 0.916 |
Respiratory Toxicity: | 0.035 |